Connect to share and comment

Sanofi sues Lilly over challenge to top diabetes drug Lantus

By Bill Berkrot and Natalie Huet NEW YORK/PARIS (Reuters) - French drugmaker Sanofi sued Eli Lilly and Co for alleged patent infringements concerning its top-selling Lantus diabetes treatment, delaying the U.S. company's plans to produce its own version of the drug. Lantus is the world's most prescribed insulin product, with annual worldwide sales of about $7 billion. It is set to lose patent protection in the United States, the world's largest pharmaceutical market, in February 2015.

Sanofi plans late-stage diabetes combo drug tests in 2014

PARIS (Reuters) - Sanofi aims to start late-stage tests for a pen device combining diabetes treatments Lantus and Lyxumia in the first half of 2014, according to slides posted on its website ahead of a presentation to investors on Monday. The French drugmaker said in May it was stepping up the development of the fixed-combination pen to sidestep an earlier setback with a similar device and take advantage of the delayed U.S. launch of competitor Novo Nordisk's new insulin. (Reporting by Elena Berton; Editing by James Regan)

Sanofi's next-generation insulin shows edge over Lantus

PARIS (Reuters) - An improved version of Sanofi's blockbuster insulin Lantus is better than the older drug at controlling blood sugar lows at night, a common side effect in diabetics treated with insulin, according two late-stage tests published on Saturday. The results for the next-generation treatment, known as U300, could strengthen Sanofi's position as it defends its no. 2 spot in the $43 billion diabetes market from rival drugs.

Sanofi boosts Lantus insulin production in Ireland

PARIS, Feb 13 (Reuters) - French drugmaker Sanofi said on Wednesday it would invest 44 million euros ($59 million) on its site in Waterford, Ireland, to boost production of its top-selling insulin, Lantus. The company, which has been reshuffling research and production sites in the United States and Europe after the patent loss of several key medicines, aims to start making Lantus at the site in 2016, Sanofi said in a statement.

Novo Nordisk shares plunge on insulin setback

The world's biggest insulin producer Novo Nordisk Monday had 10.7 billion euros ($14.4 billion) wiped off its market value after the company said US authorities had rejected its applications for two new insulin treatments. Shares in the Danish company plunged by up to 15 percent after the US Food and Drug Administration (FDA) said "approvals for Tresiba and Ryzodeg cannot be granted" until the company provides additional information. The FDA requested more cardiovascular data, which Novo Nordisk said it was unlikely to be able to provide this year.

Novo Nordisk shares plunges on insulin setback

Shares in the world's biggest insulin producer Novo Nordisk plunged by up to 15 percent on Monday after the company said US drug authorities had rejected its applications for two new insulin treatments. The Danish company said it had received a letter from the US Food and Drug Administration (FDA) stating "that approvals for Tresiba and Ryzodeg cannot be granted" until the company provides additional information. The FDA requested more cardiovascular data, which Novo Nordisk said it was unlikely to be able to provide this year.

URGENT ¥¥¥ Novo Nordisk share plunges on insulin setback

Shares in the world's biggest insulin producer Novo Nordisk plunged by 13 percent on Monday after the company said US drug authorities had rejected its applications for two new insulin treatments. The Danish company said it had received a letter from the US Food and Drug Administration stating "that approvals for Tresiba and Ryzodeg cannot be granted" until the company provides additional information. po/nsb/hd
Syndicate content